A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ, JPMA “Truly Regret” Additional Price Cuts for Long-Listed, Generic Drugs
December 27, 2011
- JPMA's Kawabe Says Additional Price Cut for Long-Listed Products is “Not a Rule”
December 22, 2011
- Cancer Patient Groups Submit Petition Asking for Elimination of Drug Lag
December 20, 2011
- Doctor Survey Shows AD at Top of Most Medically Significant Diseases in 2020
December 20, 2011
- GSK President Fauchet Appointed New Chairman, EFPIA Japan
December 20, 2011
- Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
- JCQHC Calls Attention to Contraindication of Coadministration
December 19, 2011
- Drug Pricing Subcommittee President Bessho Calls for Correction in “Across-the-Board” Bundling
December 15, 2011
- Drug Expenditure Ratio Should Be Fixed: Professor Endo, Gakushuin University
December 15, 2011
- Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
- Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
- 129 Hospitals Stopped Providing Services in Ophthalmology Since 2008: JOA
December 13, 2011
- JMA Announces View on TPP Agreement on Website
December 12, 2011
- Osaka Bio Fund Chooses Tokyo Drug Discovery Venture as No. 3 Investment Project
December 9, 2011
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
- PSUR to Be Renamed PBRER: ICH
December 5, 2011
- JACDS Council Holds Hearings on Remote Sales of OTC Drugs
December 2, 2011
- Original Drug Makers Should Let Go of Long-Listed Drugs
December 1, 2011
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…